Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Sunovion Swallows Up Cynapsus in $624 Million Deal

Fresh off its filing for a new COPD drug, Massachusetts-based Sunovion Pharmaceuticals struck a $642 million deal to acquire Toronto-based Cynapsus Therapeutics and its Parkinson’s disease drug candidate.

Read More »

U.S. FDA strengthens warning over opioid/sedative combination

The U.S. Food and Drug Administration strengthened warnings about the danger of combining opioid painkillers or cough medicines containing opioids with benzodiazepines, a common class of sedatives.

Read More »

Novartis to Dissolve Cell and Gene Therapy Unit

Novartis AG is dissolving its Cell and Gene Therapy Unit, according to Endpoints News, citing a note sent to 400 employees by division president Usman Azam.

Read More »

More Trouble for Theranos as FDA Discovers Company Cut Corners With Zika Test

Embattled Theranos has run into another testing snag, this time with its proposed blood test for the Zika virus. The company was forced to withdraw its request for emergency clearance of the test after inspectors with the U.S. Food and Drug Administration found the company did not include proper patient protections in its study, according to the Wall Street Journal.

Read More »

Stock Pops as Medivir Decides to Split into Two Companies

Medivir AB announced that it plans to split up into two independent companies.

Read More »

Express Scripts diabetes program aims to cap costs for customers

Express Scripts Holding, the largest U.S. pharmacy benefit manager, said it will implement a program in 2017 that guarantees per-patient spending caps on diabetes drug costs in an effort to limit soaring increases for its customers.

Read More »

Study finds flaws in criticism of St. Jude cyber security

University of Michigan researchers said their own experiments undermine recent allegations of security flaws in St. Jude Medical Inc.’s pacemakers and other implantable medical devices.

Read More »

FDA approves Novartis biosimilar to Amgen’s Enbrel

The U.S. Food and Drug Administration approved Novartis AG’s biosimilar version of Amgen Inc.’s arthritis drug Enbrel.

Read More »

PBMs’ Attack on Physician Dispensing and Impact on Patient Care

A White Paper from the Community Oncology Alliance (COA) looks at recent moves by Pharmacy Benefit Managers (PBMs) to increase corporate profits by declaring all physician dispensing to be out-of-network.

Read More »

Want to detect gluten on the go? There’s a device for that

A California startup has developed a portable technology that will allow consumers to test their food for gluten on the go.

Read More »

A growing problem, child malnutrition costs Philippines $7 billion in a year

Child malnutrition cost the Philippines $7 billion or nearly 3 percent of its GDP in one year in terms of education spending and lost productivity, while hunger-related stunting is on the rise among children, a global aid agency said.

Read More »

Rigel’s bleeding disorder drug clears key trial

Rigel Pharmaceuticals Inc. said its experimental drug to treat a bleeding disorder met its main goal in the first of two late-stage trials.

Read More »

Carmat jumps after first implantation of its bioprosthetic artificial heart

Carmat’s shares jumped after the French company announced the first implantation of its bioprosthetic artificial heart in a final-stage clinical trial.

Read More »

Key Parkinson’s Trial Delayed Due to Feud Between a Georgetown University Scientist and The Michael J. Fox Foundation

In late 2015, Charbel Moussa, a researcher at Georgetown University Medical Center (GUMC) in Washington, announced the results of a promising Phase I clinical trial of cancer drug nilotinib in Parkinson’s disease. A second clinical trial was expected to start in October, but is currently being delayed due to a what is being dubbed a “feud” between Moussa, Georgetown, and the Michael J. Fox Foundation.

Read More »

CRO AMRI Restructures and Cuts Jobs as Result of Euticals Acquisition

Contract research organization Albany Molecular Research (AMRI), headquartered in Albany, New York, announced that it will be restructuring specific operations in the U.S. and Europe. An unspecified number of jobs will be cut as a result.

Read More »

Lung disease therapy misses primary trial goal

Drugmaker Vectura Group Plc said its asthma therapy Flutiform had not met the primary endpoint in a late-stage trial to determine its ability to treat COPD.

Read More »

Valeant is sued over Philidor ties, alleged racketeering

Valeant Pharmaceuticals International Inc. was sued by buyers of its drugs, who accused the Canadian company of racketeering by forcing them to pay exorbitant prices.

Read More »

Researchers find first U.S. bacteria with worrisome superbug genes

New Jersey researchers said they had identified perhaps the first strain of E. Coli bacteria in the United States with mobile genes that make it resistant to two types of antibiotics now considered last-line defenses against superbugs.

Read More »

Mylan to launch generic EpiPen at half the price of original

Mylan NV said it would launch the first generic version of its allergy auto-injector EpiPen at half the price of the branded product, the drugmaker’s second step in less than a week to counter a wave of criticism over the product’s high price.

Read More »

Southeast Asia needs to up its game to combat Zika: experts

The spread of the Zika virus across tropical Southeast Asia is likely to be significantly under-reported as local health authorities fail to conduct adequate screening, regional experts said.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom